Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients.

Jong Hwa NaJeong-Han KimWon Hyeok ChoeSo Young KwonByung Chul Yoo

Published in: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi (2021)

Although TDF might be more efficient than ETV in reducing the HBsAg level in HBeAg-negative patients in a few years, HBsAg seroconversion occurred very rarely. A further large-scale, long-term study will be needed to confirm the antiviral effects on the HBsAg level.

Keyphrases

hepatitis b virus
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
emergency department
patient reported outcomes